About Urokinase plasminogen activator surface receptor
Urokinase plasminogen activator surface receptor (PLAUR) is a protein
from Homo sapiens identified by UniProt accession
Q03405, 335 residues long.
MolForge cross-references it against 0 known binders and
720 disease associations.
Target properties
| Protein name | Urokinase plasminogen activator surface receptor |
| UniProt accession | Q03405 |
| Gene | PLAUR |
| Organism | Homo sapiens |
| Length | 335 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (720)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.47
- neutrophil count · score 0.38
- leukocyte count · score 0.38
- blood protein measurement · score 0.38
- urokinase plasminogen activator surface receptor measurement · score 0.37
- basophil count · score 0.36
- high density lipoprotein cholesterol measurement · score 0.34
- myeloid white cell count · score 0.34
- Red cell distribution width · score 0.34
- monocyte percentage of leukocytes · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q03405-F1 | alphafold | PREDICTED | 81.47 | — |
Amino-acid sequence (335 residues)
MGHPPLLPLL LLLHTCVPAS WGLRCMQCKT NGDCRVEECA LGQDLCRTTI VRLWEEGEEL ELVEKSCTHS EKTNRTLSYR TGLKITSLTE VVCGLDLCNQ GNSGRAVTYS RSRYLECISC GSSDMSCERG RHQSLQCRSP EEQCLDVVTH WIQEGEEGRP KDDRHLRGCG YLPGCPGSNG FHNNDTFHFL KCCNTTKCNE GPILELENLP QNGRQCYSCK GNSTHGCSSE ETFLIDCRGP MNQCLVATGT HEPKNQSYMV RGCATASMCQ HAHLGDAFSM NHIDVSCCTK SGCNHPDLDV QYRSGAAPQP GPAHLSLTIT LLMTARLWGG TLLWT
Explore Urokinase plasminogen activator surface receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets